Dataset from A Prospective, Open-Label, Multicenter Randomized Phase III Trial to Compare The Efficacy and Safety of A Combined Regimen of Obinutuzumab and Venetoclax Versus Obinutuzumab and Chlorambucil in Previously Untreated Patients With CLL and Coexisting Medical Conditions

This open-label, multicenter, randomized Phase III study is designed to compare the efficacy
and safety of a combined regimen of obinutuzumab and venetoclax versus obinutuzumab +
chlorambucil in participants with chronic lymphocytic leukemia (CLL) and coexisting medical
conditions. The time on study treatment was approximately one year and the follow-up period
will be up to 9 years.